SCHEMBL27245481

SCHEMBL27245481

CC(C)(C)C1CC(F)(CN)CCN1C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21825490 0.87
SCHEMBL15288478 0.81
SCHEMBL4565937 0.79
SCHEMBL4978101 0.75 CHRM2 (0.32)
SCHEMBL22770535 0.75
SCHEMBL4975042 0.75
SCHEMBL2887784 0.75 CHRM2 (0.30)
SCHEMBL17393540 0.73
SCHEMBL20544034 0.73
SCHEMBL17113528 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199630-A1 IMIDAZO[1,2-B]PYRIDAZINE BASED TRICYCLIC COMPOUNDS AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) 2024-06-20 US disclosed
EP-4063370-A1 IMIDAZO[1,2-B]PYRIDAZINE BASED TRICYCLIC COMPOUNDS AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF Fundación Centro Nacional de Investigaciones Oncológicas Carlos III (ES) 2022-09-28 EP disclosed